Vascular dysfunction in adriamycin nephrosis: Different effects of adriamycin exposure and nephrosis

Nephrology Dialysis Transplantation

Volumn 23, Issue 6, 2008, Pages 1854-1860

  Ulu, Nadir ^a,b   Buikema, Hendrik ^a   Gilst, Wiek H Van ^a   Navis, Gerjan ^a  

^a UNIVERSITY OF GRONINGEN   (Netherlands)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Adriamycin; Nephrosis; Vascular dysfunction

Indexed keywords

ACETYLCHOLINE; BRADYKININ; DOXORUBICIN; SODIUM CHLORIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY BLOOD FLOW; DRUG EXPOSURE; HEART PERFUSION; HYPERCHOLESTEROLEMIA; ISOLATED HEART; MALE; NEPHROSIS; NONHUMAN; PRIORITY JOURNAL; PROTEINURIA; RAT; RENAL ARTERY; THORACIC AORTA; VASCULAR DISEASE;

ANIMALS; BLOOD PRESSURE DETERMINATION; CARDIOVASCULAR SYSTEM; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; ENDOTHELIUM, VASCULAR; MALE; NEPHROTIC SYNDROME; PROTEINURIA; RATS; RATS, WISTAR; REFERENCE VALUES; REGIONAL BLOOD FLOW; SENSITIVITY AND SPECIFICITY;

EID: 44449105616     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfm911     Document Type: Article

References (20)

1. Yeung TK, Chakrabarti K, Wilding D et al. Modification of doxorubicin-induced cardiotoxicity: manipulation of the dosage schedule. Hum Exp Toxicol 2002; 21: 607-614
2. Wapstra FH, van Goor H, de Jong PE et al. Dose of doxorubicin determines severity of renal damage and responsiveness to ACE-inhibition in experimental nephrosis. J Pharmacol Toxicol Methods 1999; 41: 69-73
3. Wapstra FH, van Goor H, Navis GJ et al. Antiproteinuric effect predicts renal protection by angiotensin-converting enzyme inhibition in rats with established adriamycin nephrosis. Clin Sci (London) 1996; 90: 393-401
4. De Boer E, Navis GJ, Tiebosch AT et al. Systemic factors determine proteinuria-induced renal damage. J Am Soc Nephrol 1999; 10: 2359-2366
5. Ito M, Oguri M, Naruse A et al. Impaired endothelium-derived relaxation in isolated thoracic aorta of rats with daunomycin-induced nephrosis. J Pharm Exp Ther 1991; 258: 388-395
6. Posadas-Sánchez R, Posadas-Romero C, Zamora-González J et al. LDL size and susceptibility to oxidation in experimental nephrosis. Mol Cell Biochem 2001; 220: 61-68
7. Wapstra FH, Navis GJ, de Jong PE et al. Chronic angiotensin II infusion but not bradykinin blockade abolishes the antiproteinuric response to angiotensin-converting enzyme inhibition in established adriamycin nephrosis. J Am Soc Nephrol 2000; 11: 490-496
8. Bertani T, Cutillo F, Zoja C et al. Tubulo-interstitial lesions mediate renal damage in adriamycin glomerulopathy. Kidney Int 1986; 30: 488-496
9. Kramer AB, Ricardo SD, Kelly DJ et al. Modulation of osteopontin in proteinuria-induced renal interstitial fibrosis. J Pathol 2005; 207: 483-492
10. Buikema H, Pinto YM, van Geel PP et al. Differential inhibition of plasma versus tissue ACE by utibapril: biochemical and functional evidence for inhibition of vascular ACE activity. J Cardiovasc Pharmacol 1997; 29: 684-691
11. Voors AA, Pinto YM, Buikema H et al. Dual pathway for angiotensin II formation in human internal mammary arteries. Br J Pharmacol 1998; 125: 1028-1032
12. Moncada S, Palmer RM, Higgs EA et al. Nitric oxide: physiology, pathophysiology and pharmacology. Pharmacol Rev 1991; 43: 109-142
13. Vásquez-Vivar J, Martasek P, Hogg N et al. Endothelial nitric oxide synthase-dependent superoxide generation from adriamycin. Biochemistry 1997; 36: 11293-11297
14. Den Hartog GJ, Boots AW, Haenen GR et al. Lack of inhibition of endothelial nitric oxide synthase in the isolated rat aorta by doxorubicin. Toxicol In Vitro 2003; 17: 165-167
15. Murata T, Yamawaki H, Yoshimoto R et al. Chronic effect of doxorubicin on vascular endothelium assessed by organ culture study. Life Science 2001; 69: 2685-2695
16. Martin W, Furchgott RF, Villani GM et al. Depression of contractile responses of rat aorta by spontaneously released endothelium derived relaxing factor. J Pharm Exp Ther 1986; 237: 529-538
17. Stroes ES, Koomans HA, de Bruin TW et al. Vascular function in the forearm of hypercholesterolaemic patients off and on lipid-lowering medication. Lancet 1995; 346: 467-471
18. Arun KH, Kaul CL, Poduri R. Tempol augments angiotensin II-induced AT2 receptor-mediated relaxation in diabetic rat thoracic aorta. J Hypertens 2004; 22: 2143-2152
19. Ito M, Naruse A, Yamamoto I et al. Nephrosis augments contractile responses to adrenoceptor agonists by the decrease in release of endothelium derived relaxing factor from the endothelial cells. J Pharm Exp Ther 1994; 269: 589-595
20. Luscher TF. Mack Forster Award Lecture. The endothelium as a target and mediator of cardiovascular disease. Eur J Clin Invest 1993; 23: 670-685